ORMP · XBRL financial data

Oramed Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ORMP's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	0*	0*	—	—	—	—	2,000	0*	0*	0*	—	—
Cost of revenue	—	—	—	—	—	—	1,987	0*	0*	0*	—	—
Gross profit	—	—	—	—	—	—	13	0*	0*	0*	—	—
Research and development	957	1,766*	1,179	1,442	2,242	1,461*	2,206	1,034	1,153	1,988*	1,594	0*
General and administrative	2,599	2,111*	1,783	1,693	847	2,134*	2,307	1,455	1,274	3,684*	2,065	2,766
Operating income (loss)	(2,893)	(3,877)*	(2,962)	(3,135)	(3,089)	(3,595)*	(4,500)	(2,489)	(2,427)	(5,672)*	(3,659)	(2,766)
Interest income	—	year only	—	—	—	—	—	—	—	—	—	—
Interest expense	826	1,211*	592	261	0*	0*	—	—	—	—	—	—
Other income (expense)	—	year only	3,552	—	—	year only	(3,616)	3,473*	—	year only	(100)	(4)
Income tax expense (benefit)	—	—	—	1,634	1,133	416*	584	(126)	11,062	(212)*	11,130	23,431
Net income (loss)	(3,222)	13,336*	1,536	9,212	(19,619)	(10,232)*	(7,642)	13,288	48,395	10,009*	38,310	78,156
Earnings per share, basic USD per share	0.08	—	0.04	0.22	(0.48)	(0.25)*	(0.19)	0.32	1.16	0.24*	0.94	1.90
Earnings per share, diluted USD per share	0.08	—	0.04	0.22	(0.48)	(0.26)*	(0.19)	0.31	1.13	0.23*	0.91	1.84
Weighted average shares, basic thousands of shares	40,446	40,541*	40,836	40,960	40,897	40,622*	41,229	41,743	41,756	40,883*	40,774	41,040
Weighted average shares, diluted thousands of shares	40,446	41,540*	41,564	41,591	40,897	39,278*	41,229	42,609	42,775	43,038*	41,970	42,501

Balance sheet

CSV

Fiscal quarters (ORMP's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	5,468	9,055	18,576	84,753	42,104	54,420	74,516	15,797	52,179	45,947	13,202	15,245
Short-term investments	49	57,713	77,733	66,206	57,455	—	—	—	—	—	—	—
Marketable securities	—	1,807	2,026	2,345	646	3,441	3,695	1,753	4,956	5,417	4,965	846
Marketable securities, non-current	2,535	1,807	2,026	2,345	646	3,524	3,524	—	—	8,371	17,967	21,866
Prepaid and other current assets	666	537	501	533	474	1,291	832	1,086	1,430	2,741	2,310	2,173
Total current assets	175,705	162,584	177,095	153,270	142,774	143,221	131,476	99,026	136,117	133,271	68,150	53,407
Property and equipment, net	923	873	819	765	718	698	671	645	614	586	561	532
Right-of-use asset	768	694	608	566	486	414	342	882	817	750	684	617
Total assets	230,893	220,551	203,652	184,223	165,081	155,278	147,539	161,684	220,493	230,864	268,847	369,643
Accounts payable	—	551	—	—	—	789	509	715	560	443	481	374
Accrued liabilities	—	605	—	—	—	740	800	841	585	1,084	1,121	1,263
Total current liabilities	78,175	53,214	33,556	3,733	5,273	5,685	5,492	3,693	6,119	19,086	10,563	10,731
Lease liability, non-current	389	342	272	236	186	156	120	648	589	540	493	484
Accumulated deficit	(170,892)	(157,556)	(156,020)	(146,808)	(166,427)	(176,616)	(184,258)	(170,970)	(122,575)	(123,436)	(85,121)	(6,965)
Total stockholders' equity	149,132	163,821	166,639	177,065	156,441	146,265	140,812	154,529	203,282	199,744	—	—
Total liabilities and equity	230,893	220,551	203,652	184,223	165,081	155,278	147,539	161,684	220,493	230,864	268,847	369,643
Common shares outstanding (cover page) thousands of shares	40,339	40,519	40,629	40,769	40,312	40,850	40,850	41,004	39,802	40,446	40,926	41,597

Cash flows

CSV

Fiscal quarters (ORMP's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(3,222)	13,336*	1,536	9,212	(19,619)	(10,232)*	(7,642)	13,288	48,395	10,009*	38,310	78,156
Stock-based compensation	852*	1,367*	1,294	1,229*	301*	1,229*	2,189	800*	719*	2,284*	1,736	1,393*
Net cash from operating activities	(694)*	(1,418)*	(1,476)	2,076*	(7,101)*	(1,911)*	(3,519)	(3,535)*	(1,625)*	(466)*	(2,915)	(200)*
Purchases of property and equipment	32*	3*	2	0*	5*	11*	3	4*	0*	2*	5	2*
Net cash from investing activities	(75,122)*	29,997*	29,998	94,655*	(34,260)*	15,424*	23,616	(54,853)*	38,364*	(1,684)*	(19,488)	4,310*
Proceeds from issuing common stock	(2)*	0*	—	—	—	—	—	—	—	—	—	—
Share repurchases	—	—	—	—	—	1,193*	—	—	361*	4,009*	—	—
Dividends paid	—	—	—	—	—	—	—	—	—	—	10,364	78*
Net cash from financing activities	74,548*	(25,000)*	(19,000)	(30,550)*	(1,291)*	(1,195)*	—	—	(361)*	(4,009)*	(10,364)	(1,949)*
Net change in cash	(1,299)*	3,587*	9,521	66,177*	(42,649)*	12,316*	20,096	(58,719)*	36,382*	(6,232)*	(32,745)	2,043*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Oramed Pharmaceuticals	15,245	not reported	(200)*	41.6M	80.5 quarters	Q2 FY26 10-QJun 30, 2026
XBiotech	109,528	not reported	(4,515)*	30.5M	24.3 quarters	Q2 FY26 10-QJun 30, 2026
Inovio Pharmaceuticals	31,526	0	(18,047)*	103.4M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
Macrogenics	113,907	32,832	(40,748)*	63.7M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Elicio Therapeutics	23,480	not reported	(8,165)*	26.3M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Coherus Oncology	82,923	not reported	(62,090)*	154.5M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Volitionrx	2,800	399	(5,160)*	13.6M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	43,287	29,105	(16,728)*	111.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Immunic	155,098	not reported	(30,998)*	13.6M	5.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.